Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

skin cancer screening doctor - Seventyfour - stock.adobe.com

Global Skin Cancer Burden Among Older Adults Surged Since 1990, Driven by Keratinocyte Cancer

By Giuliana Grossi

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Machine that delivers chemotherapy drugs

September 12th 2021

Factors of Ipilimumab/Nivolumab Success in Metastatic Melanoma Identified

Jared Kaltwasser

This new analysis of combination treatment with ipilimumab and nivolumab identified factors likely to lead to therapeutic success with the combination.

Graphic of question mark

September 10th 2021

In BRAF-Mutated Advanced Melanoma, Range of First-line Choices Brings Hope, Questions

Jared Kaltwasser

Patients with BRAF-V600 mutated metastatic melanoma have new treatment options to consider, but scientists are still waiting on additional data to help choose which first-line treatments are best for which patients.

pill graphic

September 8th 2021

Similar Therapy Tolerance Seen Among Patients With Melanoma, Regardless of Age

Jared Kaltwasser

Patients over the age of 65 had similar rates of serious adverse events, and nearly identical progression-free survival, when compared with younger patients.

patients and doctors graphic

August 31st 2021

Higher Rates of Chronic Complications Linked With Anti–PD-1 Treatment Seen in Patients With Melanoma

Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.

Photo of person with potential skin cancers

August 25th 2021

Autophagy Inhibition in BRAF-Driven Skin Cancers Raises Hopes, Questions

Jared Kaltwasser

Autophagy inhibition could help patients who develop resistance to BRAF inhibitors, but a new review shows important questions remain.

syringe on pills

August 22nd 2021

Researchers Assess ICI Resistance in Melanoma Treatment

Researchers outline factors that may inhibit immune checkpoint inhibitor efficacy in patients with melanoma.

Todd Schlesinger, MD, FAAD, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas

August 19th 2021

Dr Todd Schlesinger: Morphology, Immunosuppression Affect Actinic Keratosis Outcomes

Actinic keratosis outcomes can be affected by several variables, and these lesions need to be treated to minimize progression risk, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Doctor examining skin for cancer

August 15th 2021

New Research Aims to Solve Resistance Problems in Melanoma Therapies

Jared Kaltwasser

New strategies are currently being investigated to find out how to avoid resistance to immune checkpoint inhibitors and BRAF/MEK inhibitors.

files on a shelf

August 11th 2021

Study Finds CPT Codes Superior to ICD Codes for Quantifying Patients’ Skin Cancers

Researchers compared billing codes from electronic health records to accurately quantify how many skin cancers patients had.

Todd Schlesinger, MD, FAAD, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas

August 9th 2021

Dr Todd Schlesinger: Treatment for Early-Stage Melanomas Can Be Safely Delayed During the Pandemic

We can safely delay excising in situ and early-stage melanomas while managing our patients’ care, noted Todd Schlesinger, MD, FAAD, director, Dermatology and Laser Center of Charleston and Clinical Research Center of the Carolinas.

Rajiv Nijhawan, MD, UT Southwestern Medical Center

August 5th 2021

Dr Rajiv Nijhawan: Collaboration Advances Comprehensive Care for Patients With High-risk Skin Cancers

Collaborating with colleagues outside of dermatology helps to maximize the chances of skin cancer not coming back, especially in rare cases of noncontiguous tumors, noted Rajiv Nijhawan, MD, director of the UTSW High Risk Skin Cancer Transplant Clinic, in Dallas, Texas.

Melanoma graphic

August 3rd 2021

BRAF/MEK Inhibitors Effective in Patient With Rare Melanoma Mutation

Jared Kaltwasser

A report reviews the case of a patient with stage IV melanoma who, while having several issues with treatment toxicity, was later free of disease following treatment with BRAF and MEK inhibitors.

MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma

August 21st 2019

MDM2 Antagonists Help CDK4/6 Inhibitors Overcome Resistance in Melanoma

Laura Joszt, MA

Outside of breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have not been as successful as tumors develop resistance. New research shows that a murine double minute (MDM2) antagonist can help CDK4/6 inhibitors overcome resistance, offering a potential second-line treatment option in melanoma.

Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma

July 18th 2019

Personalized Cancer Vaccine Yields Promising Results for Patients With High-Risk Melanoma

Jaime Rosenberg

A phase 2b clinical trial is producing promising results for a personalized cancer vaccine used in patients with stage III and IV resected melanoma.

May 1st 2019

Gathering and Using Real-World Data to Improve Patient Outcomes

Laura Joszt, MA

In a session at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, speakers highlighted a pilot program to gather and use real-world evidence to compare outcomes at 7 large academic medical centers for patients with rheumatoid arthritis, multiple sclerosis, and malignant melanoma.

February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.

February 12th 2019

Rutgers' Janice Mehnert, MD, on Biomarkers, Being Inclusive in Clinical Trials, and Taking Time to Weigh the Options

From her vantage point at Rutgers Cancer Institute of New Jersey, Janice Mehnert, MD, has had a front-row seat to the immuno-oncology revolution. Mehnert returned to her alma mater in 2007, and since 2014, she has headed Rutgers’ Phase I/ Developmental Therapeutics Program; she is also head of the melanoma research team. Her work on the KEYNOTE-028 trial has produced important results in multiple cancers, including neuroendocrine tumors, thyroid cancer, small cell lung cancer, and, recently, advanced ovarian cancer.

Immunotherapy Improves Survival in Metastatic Melanoma

November 7th 2018

Immunotherapy Improves Survival in Metastatic Melanoma

David Bai, PharmD

The use of CTLA-4, PD-1, or a combination approach achieved high response rates and improved overall survival in patients with CDKN2A mutations with metastatic melanoma, based on the results of a study by Helgadottir et al.

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

November 1st 2018

New Melanoma Guidelines Identify Recommended Treatments, Weigh In on Genetic Testing

Laura Joszt, MA

New guidelines released by the American Academy of Dermatology will help physicians provide the best treatment for more than 1 million Americans living with melanoma, the deadliest form of skin cancer. The guidelines also highlight the importance of discussions between physicians and patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions